Neuronetics Announces Chief Financial Officer Transition
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) announced that Steven E. Pfanstiel will resign as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the company and will remain through May 1, 2026 to support an orderly transition.
The company said the departure is not due to any dispute and that it has launched a search for a replacement. Neuronetics also reaffirmed its fiscal 2026 financial guidance previously provided on March 17, 2026.
Positive
- CFO transition planned with handover through May 1, 2026
- Fiscal 2026 guidance reaffirmed on April 6, 2026
Negative
- Ongoing CFO vacancy until replacement is hired
- Search for replacement introduces short-term leadership uncertainty
News Market Reaction – STIM
On the day this news was published, STIM declined 10.23%, reflecting a significant negative market reaction. Argus tracked a peak move of +34.2% during that session. Argus tracked a trough of -6.0% from its starting point during tracking. Our momentum scanner triggered 57 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $125.74M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
STIM was up 2.01% while peers were mixed: BSGM up 39.91%, ELMD up 1.94%, CVRX up 0.44%, TLSI down 3.09%, BWAY down 7.5%, suggesting a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Earnings results | Positive | -9.9% | Full-year 2025 results and 2026 guidance following Greenbrook acquisition. |
| Mar 17 | Leadership change | Positive | -9.9% | Appointment of new CEO with large RSU inducement grant. |
| Mar 3 | Earnings call scheduling | Neutral | -1.6% | Announcement of date and time for Q4 2025 results call. |
| Feb 10 | Prelim earnings | Positive | +23.3% | Preliminary 2025 revenue and cash flow metrics ahead of full results. |
| Nov 20 | Conference participation | Neutral | -12.8% | Planned appearance at Piper Sandler healthcare conference fireside chat. |
Recent news has produced mixed reactions: strong preliminary results were followed by a large gain, while later earnings and leadership changes coincided with notable declines.
Over the last few months, Neuronetics reported strong growth, with Q4 2025 revenue $41.8M and FY2025 revenue $149.2M, plus 2026 guidance given on Mar 17, 2026. Preliminary results on Feb 10, 2026 were followed by a 23.29% gain, but the full earnings release and CEO transition on Mar 17, 2026 coincided with a -9.93% move. Earlier, routine announcements like conference participation on Nov 20, 2025 and the earnings call scheduling on Mar 3, 2026 also saw negative reactions, indicating sensitivity around news flow.
Regulatory & Risk Context
An effective shelf prospectus dated March 17, 2026 registers up to 20,737,061 shares of common stock for resale by selling stockholders. The company receives no proceeds from these sales, and the filing notes that the registered shares represent a significant percentage of outstanding stock, which could affect market price if sold concurrently.
Market Pulse Summary
The stock dropped -10.2% in the session following this news. A negative reaction despite reaffirmed Fiscal Year 2026 guidance would fit a pattern where leadership and earnings news on March 17, 2026 coincided with a -9.93% move. The announcement of the CFO’s departure by May 1, 2026 could heighten governance concerns. An active resale shelf and prior sharp swings around financial updates suggest that downside reactions to corporate transitions have occurred before.
AI-generated analysis. Not financial advice.
Reaffirms Fiscal Year 2026 Financial Guidance
MALVERN, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company. He will remain with the Company through May 1, 2026 to support an orderly transition. Mr. Pfanstiel’s decision to resign is not the result of any dispute or disagreement with the Company or the Company’s management or Board on any matter relating to the Company’s operations, policies, or practices. The Company has launched a search to identify Mr. Pfanstiel’s replacement.
In conjunction with today's announcement, Neuronetics reaffirmed the financial guidance it provided during its fourth quarter 2025 earnings call on March 17, 2026.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal years, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to maintain positive cash flow. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
